Journal Club 9/22/23

Last week, our researchers and physicians discussed a paper regarding the association of higher Ocrelizumab exposure with reduced disability progression in MS. Ocrelizumab, or Ocrevus, is a prescription drug commonly used to treat both progressive and relapsing-remitting MS. Ocrelizumab was shown to reduce new MRI lesion counts, and resulted in a lower annual relapse rate in RRMS patients. These findings suggest that higher exposure to Ocrelizumab may result in improved control of disability progression.

#tischms #curems #findacureforMS #tischMSRCNY